Sign In
Buy QTTB
$11.88
-0.770 (-6.09%)
At Close: Jun 23, 2026
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
06:59am, Tuesday, 05'th Nov 2024
WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued cli
Q32 Bio to Participate in Upcoming September Investor Conferences
06:59am, Thursday, 29'th Aug 2024
WALTHAM, Mass. , Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis
Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097
03:40am, Thursday, 29'th Aug 2024
Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of loc
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 91.69%: Read This Before Placing a Bet
10:55am, Monday, 12'th Aug 2024
The consensus price target hints at a 91.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis
06:59am, Tuesday, 09'th Jul 2024
-- Exceeded enrollment target due to patient demand; trial size increased to 121 patients -- -- Bempikibart topline results remain on track to be released in Q4'24 -- WALTHAM, Mass. , July 9, 2024 /PR
Q32 Bio Joins Russell 3000® Index
06:59am, Monday, 01'st Jul 2024
WALTHAM, Mass. , July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis,
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
06:59am, Thursday, 09'th May 2024
-- Completed enrollment in bempikibart alopecia areata (AA) Phase 2 clinical trial, with topline results expected in Q4'24; enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial rema
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
07:00am, Wednesday, 03'rd Apr 2024
WALTHAM, Mass. , April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasi
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
04:15pm, Monday, 25'th Mar 2024
-- Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA) Phase 2 clinical trials and commencement of ADX-097 Phase 2 renal basket clinica
